Sustained clinical improvement
By day 29, 17 (41.5%) of 41 patients in the 0.12 mg/kg group, 13 (31.7%) of 41 patients in the 0.2 mg/kg group, 13 (29.5%) of 44 patients in the 0.3 mg/kg group, and 13 of 41 patients (31.7%) in the placebo group achieved sustained clinical improvement. When compared to the placebo group, the percentage of patients who experienced sustained clinical improvement in the meplazumab 0.12 mg/kg group increased by 30.9% (Supplementary Table 